Achiko AG (Achiko AG) Change In Working Capital : $0.00 Mil (TTM As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Achiko AG Change In Working Capital?

Achiko AG's change in working capital for the quarter that ended in Jun. 2022 was $0.00 Mil.

Achiko AG's change in working capital for the fiscal year that ended in Dec. 2021 was $0.00 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Achiko AG Change In Working Capital Historical Data

The historical data trend for Achiko AG's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG Change In Working Capital Chart

Achiko AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Change In Working Capital

Achiko AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Change In Working Capital	Get a 7-Day Free Trial			-	-	-	-	-

Achiko AG Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Achiko AG Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Achiko AG's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Achiko AG (Achiko AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (OTCPK:ACHKF) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tessinerplatz 7, Zurich, CHE, CH-8002

Website

https://www.achiko.com

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.